查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930051

全球干细胞市场：市场规模、占有率、成长率、产业分析、按类型、应用和地区划分的考量、未来预测（2025-2034）

Stem Cells Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 请询问到货日

价格

干细胞市场成长因子

预计2025年全球干细胞市场规模将达到193.4亿美元，并在2026年成长至220.9亿美元。在预测期内，预计到2034年，市场规模将达到799.5亿美元，2026年至2034年的复合年增长率（CAGR）为17.45%。北美地区在2025年将以53.10%的市占率领先，这主要得益于活跃的研发活动、干细胞疗法的高普及率、监管支持以及不断增加的临床试验活动。

干细胞具有分化成各种特殊细胞的能力，广泛应用于再生医学和治疗药物的研发。慢性疾病的增加以及对新型疗法日益增长的需求，正推动全球范围内对研究项目、临床试验和产品开发的大量投资。

市场驱动因素

干细胞市场的成长主要得益于其在研究和治疗领域应用范围的不断扩大。干细胞正越来越多地应用于再生医学、疾病建模、药物研发和临床应用。利用人类多能干细胞进行的临床试验数量稳定成长，其中大部分研究由美国、中国、日本和英国进行。

政府主导的各项措施和资助计画也进一步加速了市场成长。例如，2023年5月，马里兰州干细胞研究委员会拨款超过1,410万美元，用于促进干细胞技术的创新研究。此外，市场参与者之间的联盟和收购，例如Bio-Techne于2022年7月收购Namocell，正在增强研发能力并拓展产品线。

市场限制因子

儘管潜力巨大，但该市场仍面临着与伦理问题和监管复杂性相关的挑战。特别是就人类胚胎干细胞（ES细胞）而言，围绕胚胎破坏、安全问题以及未经FDA批准的脐带血衍生产品的风险等伦理争议，可能会阻碍其在某些地区的应用和研究。

市场趋势

一个主要趋势是诱导多能干细胞（iPS细胞）的出现，它可作为ES细胞的替代品。 iPS细胞由成体体细胞重编程而来，获得多能性，从而消除了伦理问题，使其成为疾病建模、药物研发和再生医学的理想选择。富士胶片细胞动力学公司和其他公司已推出iPS细胞衍生试剂盒，以推进中枢神经系统（CNS）药物的研究。

另一个趋势是注重合作和协同研究。例如，Pluristyx 于 2023 年 7 月与 Stem Genomics 合作，评估多能干细胞系的基因组稳定性。 Cordlife Hong Kong Limited 也正与 Hong Kong Regen MedTech 合作，以增强基于间质干细胞 (MSC) 的疗法。

依细分市场分析

依细胞类型：市场细分为间质干细胞 (MSC)、胚胎干细胞 (ESC)、成体干细胞 (ASC) 和诱导多能干细胞 (iPS 细胞)。由于再生医学和研究应用的高需求，MSC 在 2024 年占最大占有率。然而，由于其伦理优势和多样化的应用潜力，预计 iPS 细胞将实现最高的复合年增长率。

依应用：市场细分为研发及临床应用。 2024年，研发领域占主导地位，这主要得益于干细胞在疾病模型建构和类器官开发中的应用日益广泛。在神经系统疾病、心臟病和罕见疾病再生医学的推动下，临床应用预计将在预测期内呈现最高的成长率。

按最终用户划分：2024年，製药和生物技术公司占最大占有率，这主要得益于大规模临床研究和基于诱导多能干细胞（iPS细胞）的研究的普及。由于合作研究的增加和政府资助的增加，学术和研究机构预计将以最高的复合年增长率成长。

区域展望

北美市场占主导地位，预计2025年市场规模将达到102.7亿美元，这得益于其强大的临床试验、完善的研究基础设施和完善的监管审批体系。预计欧洲市场将保持稳定成长，其中德国和英国在罕见疾病治疗领域的研发投资处于领先地位。亚太地区预计将呈现最高的复合年增长率，这主要得益于临床试验的增加、专业人才的涌现以及政府对干细胞研究的投入。预计到2026年，日本市场规模将达到11亿美元，中国将达到18.6亿美元，印度将达到6.1亿美元。拉丁美洲以及中东和非洲的市场占有率较低，主要是由于应用范围和基础设施有限。

报告范围

本报告对全球干细胞市场进行了全面分析，重点关注市场规模、成长趋势、细胞类型、应用、终端用户、区域分析、竞争格局、市场驱动因素、限制因素和新兴趋势。报告涵盖了近期市场驱动因素，并为利害关係人提供策略洞察，以掌握成长机会。

市场扩张的驱动因素包括干细胞在再生医学、疾病建模和治疗开发等领域的广泛应用，以及投资增加、政府资助和产业参与者之间的合作。诱导多能干细胞（iPS细胞）作为胚胎干细胞的符合伦理的替代方案，其兴起正进一步加速市场接受度，并支持慢性病、罕见疾病和神经系统疾病的研发和临床应用。

儘管伦理问题、监管挑战和安全问题仍然需要考虑，但临床试验的持续增加、创新产品的推出以及产学研合作的日益密切，都凸显了该市场的韧性和长期潜力。总体而言，干细胞市场预计将持续扩张，为利害关係人提供机会，以掌握全球对先进疗法和研究解决方案日益增长的需求。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 干细胞研究资助计画概述
  • 主要国家和地区相关慢性疾病的盛行率/发生率
  • 主要公司新产品发布
  • 主要公司研发管线分析
  • 干细胞市场主要新创企业概览
  • 主要产业趋势：併购合作关係
  • 新冠疫情对市场的影响

第五章：全球干细胞市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依细胞类型划分
    • 胚胎干细胞 (ESCs)
    • 间质干细胞 (MSCs)
    • 成体干细胞
    • 诱导性多能干细胞 (iPSCs)
  • 市场分析、洞察与预测：依应用领域划分
    • 研究
    • 临床
  • 市场分析、洞察与预测：依最终用户划分
    • 医院
    • 製药和生技公司
    • 学术和研究机构机构
    • 其他
  • 市场分析、洞察与预测：按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美干细胞市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲干细胞市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国王国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区干细胞市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲干细胞市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

章节10：中东与非洲干细胞市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • PromoCell GmbH
    • AcceGen
    • Bio-Techne
    • Cellular Engineering Technologies
    • Merck KgaA
    • Thermo Fisher Scientific Inc.
    • Lonza
    • Miltenyi Biotec B.V. &Co. KG
    • STEMCELL Technologies
Product Code: FBI105138

Growth Factors of stem cells Market

The global stem cells market was valued at USD 19.34 billion in 2025 and is projected to grow to USD 22.09 billion in 2026. Over the forecast period, the market is expected to reach USD 79.95 billion by 2034, exhibiting a CAGR of 17.45% from 2026 to 2034. North America led the market in 2025 with a 53.10% share, driven by strong research and development activities, high adoption of stem cell therapies, regulatory support, and increasing clinical trial activity.

Stem cells, with their ability to differentiate into specialized cells, are widely applied in regenerative medicine and therapeutic development. The rise in chronic diseases and demand for novel therapies have fueled significant investment in research initiatives, clinical trials, and product development globally.

Market Drivers

The growth of the stem cells market is primarily driven by the expansion of applications in research and therapeutics. Stem cells are increasingly utilized in regenerative medicine, disease modeling, drug discovery, and clinical applications. Clinical trials involving human pluripotent stem cells have increased steadily, with the U.S., China, Japan, and the U.K. conducting the majority of such studies.

Government-backed initiatives and funding programs further accelerate market growth. For example, the Maryland Stem Cell Research Commission allocated over USD 14.1 million in May 2023 to promote innovative research in stem cell technologies. Collaborations and acquisitions among market players, such as Bio-Techne acquiring Namocell in July 2022, enhance R&D capabilities and expand the product pipeline.

Market Restraints

Despite its potential, the market faces challenges related to ethical concerns and regulatory complexities, especially with human embryonic stem cells (ESCs). Ethical debates surrounding embryo destruction, safety concerns, and the risk of non-FDA-approved umbilical cord-derived products can hamper adoption and research in certain regions.

Market Trends

One key trend is the emergence of induced pluripotent stem cells (iPSCs) as an alternative to ESCs. iPSCs eliminate ethical concerns by reprogramming adult somatic cells to obtain pluripotency, making them ideal for disease modeling, drug discovery, and regenerative therapies. Companies such as FUJIFILM Cellular Dynamics have launched iPSC-derived kits to advance CNS drug research.

Another trend is the focus on partnerships and collaborations. For instance, Pluristyx, Inc. partnered with Stem Genomics in July 2023 to evaluate the genomic stability of pluripotent stem cell lines, and Cordlife Hong Kong Limited collaborated with Hong Kong Regen MedTech to enhance MSC-based therapies.

Segmentation Analysis

By Cell Type: The market is categorized into Mesenchymal Stem Cells (MSCs), Embryonic Stem Cells (ESCs), Adult Stem Cells (ASCs), and iPSCs. MSCs held the largest share in 2024 due to their high demand in regenerative medicine and research applications, while iPSCs are projected to register the fastest CAGR owing to their ethical advantages and diverse applications.

By Application: The market is segmented into research and clinical applications. The research segment dominated in 2024, driven by increasing use of stem cells in disease modeling and organoid development. The clinical segment is expected to record the fastest growth over the forecast period, supported by regenerative therapies for neurological disorders, cardiac diseases, and rare conditions.

By End-user: Pharmaceutical and biotechnology companies accounted for the largest share in 2024 due to extensive clinical studies and adoption of iPSC-based research. Academic and research institutes are expected to grow at the highest CAGR as collaborative research and government funding increase.

Regional Insights

North America dominated the market with USD 10.27 billion in 2025, supported by robust clinical trials, research infrastructure, and regulatory approvals. Europe is projected to grow steadily, with Germany and the U.K. leading R&D investments in rare disease therapies. Asia Pacific is expected to exhibit the highest CAGR, driven by increasing clinical trials, skilled professionals, and government investments in stem cell research. Japan is projected to reach USD 1.10 billion by 2026, China USD 1.86 billion, and India USD 0.61 billion. Latin America and the Middle East & Africa accounted for lower shares due to limited adoption and infrastructure.

Competitive Landscape

The market is highly competitive, with leading companies focusing on R&D, acquisitions, collaborations, and new product launches. Key players include Thermo Fisher Scientific, Merck KGaA, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne, AcceGen, Lonza, PromoCell GmbH, and MEDIPOST Co. Strategic partnerships, such as Thermo Fisher's collaboration with UCSF for cell therapy production in March 2023, strengthen technological capabilities and market presence.

Key Industry Developments

  • December 2023: GenCure partnered with the University of Texas at San Antonio for cellular therapy development.
  • August 2023: BlueRock Therapeutics and bit.bio signed an agreement for iPSC-derived Treg therapies.
  • July 2023: PromoCell GmbH launched PromoExQ MSC Growth Medium XF for hMSC expansion.
  • June 2023: FUJIFILM Cellular Dynamics launched its iPSC-derived Blood-Brain Barrier Isogenic Kit.

Report Coverage

The report provides a comprehensive analysis of the global stem cells market, focusing on market size, growth trends, cell types, applications, end-users, regional analysis, competitive landscape, market drivers, restraints, and emerging trends. It encompasses factors driving the market over recent years and offers strategic insights for stakeholders to capitalize on growth opportunities.

Conclusion

The global stem cells market, valued at USD 19.34 billion in 2025, is poised for significant growth, reaching USD 22.09 billion in 2026 and projected to attain USD 79.95 billion by 2034, reflecting a robust CAGR of 17.45% during 2026-2034. North America maintained its leading position in 2025, driven by strong R&D investments, high adoption of stem cell therapies, and regulatory support, while Asia Pacific is expected to emerge as the fastest-growing region due to increasing clinical trials, skilled professionals, and government initiatives.

Market expansion is fueled by the growing applications of stem cells in regenerative medicine, disease modeling, and therapeutic development, coupled with rising investments, government funding, and collaborations among industry players. The rise of iPSCs as an ethical alternative to embryonic stem cells has further accelerated market adoption, supporting research and clinical applications across chronic, rare, and neurological diseases.

While ethical concerns, regulatory challenges, and safety issues remain considerations, the continuous growth in clinical trials, innovative product launches, and academic-industry partnerships underscores the market's resilience and long-term potential. Overall, the stem cells market is positioned for sustained expansion, with opportunities for stakeholders to capitalize on the increasing demand for advanced therapies and research solutions globally.

Segmentation By Cell Type

  • Embryonic Stem Cells (ESCs)
  • Mesenchymal Stem Cells (MSCs)
  • Adult Stem Cells
  • Induced Pluripotent Stem Cells (iPSCs)

By Application

  • Research
  • Clinical

By End-user

  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

By Region

  • North America (By Cell Type, Application, End-user, Country/Sub-Region)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Cell Type, Application, End-user, Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Cell Type, Application, End-user, Country/Sub-Region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Cell Type, Application, End-user, Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • The Middle East & Africa (By Cell Type, Application, End-user, Country/Sub-Region)
    • South Africa (By Application)
    • GCC (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Funding Initiatives for Stem Cell Research
  • 4.2. Prevalence/Incidence of Relevant Chronic Disorders - By Key Countries/Region
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Snapshot of Key Start-ups in the Stem Cells Market
  • 4.6. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.7. Impact of COVID-19 on the Market

5. Global Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Cell Type
    • 5.1.1. Embryonic Stem Cells (ESCs)
    • 5.1.2. Mesenchymal Stem Cells (MSCs)
    • 5.1.3. Adult Stem Cells
    • 5.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Research
    • 5.2.2. Clinical
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Pharmaceutical and Biotechnology Companies
    • 5.3.3. Academic & Research Institutes
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Cell Type
    • 6.1.1. Embryonic Stem Cells (ESCs)
    • 6.1.2. Mesenchymal Stem Cells (MSCs)
    • 6.1.3. Adult Stem Cells
    • 6.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Research
    • 6.2.2. Clinical
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Pharmaceutical and Biotechnology Companies
    • 6.3.3. Academic & Research Institutes
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Cell Type
    • 7.1.1. Embryonic Stem Cells (ESCs)
    • 7.1.2. Mesenchymal Stem Cells (MSCs)
    • 7.1.3. Adult Stem Cells
    • 7.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Research
    • 7.2.2. Clinical
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Pharmaceutical and Biotechnology Companies
    • 7.3.3. Academic & Research Institutes
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Application
    • 7.4.2. Germany
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Spain
      • 7.4.4.1. By Application
    • 7.4.5. Italy
      • 7.4.5.1. By Application
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Application
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Application

8. Asia Pacific Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Cell Type
    • 8.1.1. Embryonic Stem Cells (ESCs)
    • 8.1.2. Mesenchymal Stem Cells (MSCs)
    • 8.1.3. Adult Stem Cells
    • 8.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Research
    • 8.2.2. Clinical
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Pharmaceutical and Biotechnology Companies
    • 8.3.3. Academic & Research Institutes
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Application
    • 8.4.2. China
      • 8.4.2.1. By Application
    • 8.4.3. India
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Cell Type
    • 9.1.1. Embryonic Stem Cells (ESCs)
    • 9.1.2. Mesenchymal Stem Cells (MSCs)
    • 9.1.3. Adult Stem Cells
    • 9.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Research
    • 9.2.2. Clinical
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Pharmaceutical and Biotechnology Companies
    • 9.3.3. Academic & Research Institutes
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Stem Cells Market Analysis, Insights and Forecast,2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Cell Type
    • 10.1.1. Embryonic Stem Cells (ESCs)
    • 10.1.2. Mesenchymal Stem Cells (MSCs)
    • 10.1.3. Adult Stem Cells
    • 10.1.4. Induced Pluripotent Stem Cells (iPSCs)
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Research
    • 10.2.2. Clinical
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals
    • 10.3.2. Pharmaceutical and Biotechnology Companies
    • 10.3.3. Academic & Research Institutes
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Application
    • 10.4.2. South Africa
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. PromoCell GmbH
      • 11.2.1.1. Overview
      • 11.2.1.2. Cell Type
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. AcceGen
      • 11.2.2.1. Overview
      • 11.2.2.2. Cell Type
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bio-Techne
      • 11.2.3.1. Overview
      • 11.2.3.2. Cell Type
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Cellular Engineering Technologies
      • 11.2.4.1. Overview
      • 11.2.4.2. Cell Type
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck KgaA
      • 11.2.5.1. Overview
      • 11.2.5.2. Cell Type
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Thermo Fisher Scientific Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Cell Type
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Lonza
      • 11.2.7.1. Overview
      • 11.2.7.2. Cell Type
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Miltenyi Biotec B.V. & Co. KG
      • 11.2.8.1. Overview
      • 11.2.8.2. Cell Type
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. STEMCELL Technologies
      • 11.2.9.1. Overview
      • 11.2.9.2. Cell Type
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 2: Global Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 3: Global Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 4: Global Stem Cells Market Revenue (USD billion) Forecast, by Region,2021-2032
  • Table 5: North America Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 6: North America Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 7: North America Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 8: North America Stem Cells Market Revenue (USD billion) Forecast, By Country,2021-2032
  • Table 9: U.S. Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 10: Canada Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 11: Europe Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 12: Europe Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 13: Europe Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 14: Europe Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 15: Germany Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 16: U.K. Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 17: France Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 18: Italy Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 19: Spain Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 20: Scandinavia Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 21: Rest of Europe Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 22: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 23: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 24: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 25: Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 26: India Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 27: China Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 28: Japan Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 29: South Korea Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 30: Australia Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 31: Rest of Asia Pacific Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 32: Latin America Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032

Table 33: Latin America Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032

  • Table 34: Latin America Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 35: Latin America Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 36: Brazil Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 37: Mexico Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 38: Rest of Latin America Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 39: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, by Cell Type,2021-2032
  • Table 40: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, by Application,2021-2032
  • Table 41: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, by End-user,2021-2032
  • Table 42: Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, By Country/ Sub-region,2021-2032
  • Table 43: GCC Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 44: South Africa Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032
  • Table 45: Rest of Middle East & Africa Stem Cells Market Revenue (USD billion) Forecast, By Application,2021-2032

List of Figures

  • Figure 1: Global Stem Cells Market Revenue Breakdown (USD billion, %) by Region,2025 &2034
  • Figure 2: Global Stem Cells Market Value Share (%), by Cell Type,2025 &2034
  • Figure 3: Global Stem Cells Market Value Share (%), by Application,2025 &2034
  • Figure 4: Global Stem Cells Market Value Share (%), by End-user,2025 &2034
  • Figure 5: Global Stem Cells Market Value (USD billion), by Region,2025 &2034
  • Figure 6: North America Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 7: North America Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 8: North America Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 9: North America Stem Cells Market Value Share (%), by Application,2025
  • Figure 10: North America Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 11: North America Stem Cells Market Value Share (%), by End-user,2025
  • Figure 12: North America Stem Cells Market Value (USD billion), By Country/Sub-region,2025 &2034
  • Figure 13: North America Stem Cells Market Value Share (%), By Country/Sub-region,2025
  • Figure 14: Europe Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 15: Europe Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 16: Europe Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 17: Europe Stem Cells Market Value Share (%), by Application,2025
  • Figure 18: Europe Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 19: Europe Stem Cells Market Value Share (%), by End-user,2025
  • Figure 20: Europe Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 21: Europe Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 22: Asia Pacific Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 23: Asia Pacific Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 24: Asia Pacific Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 25: Asia Pacific Stem Cells Market Value Share (%), by Application,2025
  • Figure 26: Asia Pacific Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 27: Asia Pacific Stem Cells Market Value Share (%), by End-user,2025
  • Figure 28: Asia Pacific Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 29: Asia Pacific Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 30: Latin America Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 31: Latin America Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 32: Latin America Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 33: Latin America Stem Cells Market Value Share (%), by Application,2025
  • Figure 34: Latin America Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 35: Latin America Stem Cells Market Value Share (%), by End-user,2025
  • Figure 36: Latin America Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 37: Latin America Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 38: Middle East & Africa Stem Cells Market Value (USD billion), by Cell Type,2025 &2034
  • Figure 39: Middle East & Africa Stem Cells Market Value Share (%), by Cell Type,2025
  • Figure 40: Middle East & Africa Stem Cells Market Value (USD billion), by Application,2025 &2034
  • Figure 41: Middle East & Africa Stem Cells Market Value Share (%), by Application,2025
  • Figure 42: Middle East & Africa Stem Cells Market Value (USD billion), by End-user,2025 &2034
  • Figure 43: Middle East & Africa Stem Cells Market Value Share (%), by End-user,2025
  • Figure 44: Middle East & Africa Stem Cells Market Value (USD billion), By Country/ Sub-region,2025 &2034
  • Figure 45: Middle East & Africa Stem Cells Market Value Share (%), By Country/ Sub-region,2025
  • Figure 46: Global Stem Cells Market Share (%), By Company,2025